RMi Pre-opening: Ugly

March 9, 2026 7:51am

Although never give up the tick, investors should tiptoe in, given the dearth of February and March’s losses for possible set-ups

We are all observers on this geo-political “event,” at NO time be out-of-sight

Pre-Open Signals: 4 Negative and 2 Positive Indications

Remember that overnight action in futures don't necessarily translate into actual trading in today’s regular stock market session.

Never leave retail investor uninformed … I say what others won’t, so you can KNOW what others can’t! 

Say/write less, mean more …

RMi Closing Bell: What happened Friday, more declines as econ added to the negative mood… https://www.regmedinvestors.com/articles/14339

RMI Financing Note: Solid Biosciences (SLDB) $240 M Private Placement … https://www.regmedinvestors.com/articles/14340   

I chose to speak-up when many analysts, brokers and commentators have shut-up!

Monday: The pre-open Dow futures are DOWN -1.25% or (-595 points), the S&P futures are DOWN -1.11% or (-75 points) and the Nasdaq futures are DOWN -1.15% or (-283 points)

• U.S. stock futures are dropping, Monday 3/9
• European markets fell -2% on Middle East turmoil as oil price surges
• Asia Pacific markets are also in the red

Economic Data: NONE

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

• Friday’s (my) 40-company covered sector’s advance/decline line opened negative with 7 incliners, 30 decliners and 3 flats, ending with a negative close of 14 incliners, 24 decliners and 2 flats

• Friday: The Dow closed DOWN -453.19 points or -0.95%, the S&P closed DOWN -90.69 points or -1.33% while the Nasdaq closed DOWN -361.307 points or -1.59%

• Thursday: The Dow closed DOWN -784.67 points or -1.61%, the S&P closed DOWN -38.79 points or -0.56% while the Nasdaq closed DOWN -58.498 points or -0.26%
• Wednesday: The Dow closed up +238.14 points or +0.49%, the S&P closed UP +52.87 points or +0.78% while the Nasdaq closed UP +290.793 points or +1.29%
• Tuesday: The Dow closed DOWN -403.51 points or -0.83%, the S&P closed DOWN -64.99 points or -0.94% while the Nasdaq closed DOWN -232.167 points or -1.02%
• Monday: The Dow closed DOWN -73.14 points or -0.15%, the S&P closed UP +2.74 points or +0.04% while the Nasdaq closed UP +80.646 points or +0.36%

• Last week: The S&P 500 was down -2%, the Dow -0.3% and the Nasdaq was down -1.2%.
• The previous week: The Dow finished down -1.3% for the week, the NASDAQ declined 0.9%, and the S&P 500 slipped -2%. 
• February: the Dow inclined +0.2%, the Nasdaq dived -3.3% and S&P 500 declined -1%.

Q1/26 – Q1 – March – 1 positive and 4 negative closes

• February – 1 market holiday, 11 positive and 8 negative closes
• January – 2 holiday, 2 neutral, 9 negative and 9 positive closes 

Q4/25:

• December, 1 holiday, 8 positive and 12 negative closes
• November, 1 holiday, 8 positive and 11 negative sessions
• October, 1 neutral, 10 positive and 12 negative closes

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

• Multiple earnings coming as sector releases Qs and FY25 …

Arrowhead Pharmaceuticals (ARWR) closed down -$3.78 after Thursday’s -$1.50 after Wednesday’s +$1.00 with a negative -$1.72 or -2.88% pre-open

Solid Biosciences (SLDB) closed up +$1.14 with a positive +$0.75 or +11.11% pre-open post offering

uniQure NV (QURE) closed up +$3.62 after Thursday’s +$1.61 with a positive +$5.03 or +35.25% pre-open

Alnylam Pharmaceuticals (ALNY) closed up +$0.15 after Thursday’s $6.79 after Wednesday’s +$8.65 after Tuesday’s -$6.42 after Monday’s -$7.85 with a negative -$4.66 or -1.45% pre-open

Ionis Pharmaceuticals (IONS) closed down -$1.12 after Thursday’s -$4.29, Wednesday’s +$0.79, Tuesday’s -$3.30 and Monday’s +$0.81 with a negative -$0.10 or -0.14% pre-open

Vertex (VRTX) closed down -$4.13 after Thursday’s -$17.07, Wednesday’s +$3.62, Tuesday’s -$11.76 and Monday’s -$10.80 with aa negative -$2.57 or -0.56% pre-open   

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

Markets fell steadily last week as the Iran war sent oil prices skyrocketing.

• All the key indexes are below their 50-day moving averages.
• The CBOE Volatility Index, or VIX, shot up on Friday to just above its October and November 2025 peaks, but still well below the April 2025 high.

“I hate to be considered negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

Are the dice … hot, as they say it is STILL a “crap shoot”        

• Keep that in mind, if there is a batch of buying opportunities. If you take advantage, you have to be nimble, cutting losers quickly and not letting small winners turn into losers. 

Investors has been looking for further insight into sector earnings; the Q4 and FY25 earnings reporting cycle. So far …

• Tuesday - 2/24 – AxoGen (AXGN), Beam Therapeutics (BEAM) and Supernus Therapeutics (SUPN)
• Wednesday – 2/25 – MiMedx (MDXG), Ionis Pharmaceuticals (IONS) and Sarepta Therapeutics (SRPT)
• Thursday – 2/26 – Intellia Therapeutics (NTLA), Wave Life Sciences (WVE), Mesoblast (MESO), Vericel (VCEL) and BioLife Solutions (BLFS)
• Monday – 3/2 uniQure NV (QURE)
• Thursday - 3/5 Regenxbio (RNX)
• Tuesday – 3/10 – BioNTech, SE (BNTX)

Welcome to my world of defining the “grey’ in our universe!

• I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!
• if I wanted to be liked, I wouldn’t have been an analyst/journalist.

March – 1st week

• 3/6 - Friday closed negative with 14 incliners, 24 decliners and 2 flats
• 3/5 – Thursday closed negative with 7 incliners, 32 decliners and 1 flat
• 3 /4 – Wednesday closed positive with 32 incliners, 6 decliners and 2 flats
• 3/3 - Tuesday closed negative with 2 incliners, 36 decliners and 2 flats
• 3/2 - Monday closed negative with 15 incliners, 23 decliners and 3 flats

February – last week

• 2/27 – Friday closed negative with 12 incliners, 26 decliners and 2 flats
• 2/26 – Thursday closed positive with 24incliners, 14 decliners and 2 flats
• 2/25 – Wednesday closed positive with 20 incliners, 19 decliners and 1 flat
• 2/24 - Tuesday closed positive with 32 incliners, 5 decliners and 3 flats
• 2/23 - Monday closed positive with 24 incliners, 13 decliners and 3 flats

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

• I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.